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MicroRNAs in the etiology of colorectal cancer: pathways and
clinical implications
Ashlee M. Strubberg and Blair B. Madison*
ABSTRACT
MicroRNAs (miRNAs) are small single-stranded RNAs that repress
mRNA translation and trigger mRNA degradation. Of the ∼1900
miRNA-encoding genes present in the human genome, ∼250
miRNAs are reported to have changes in abundance or altered
functions in colorectal cancer. Thousands of studies have
documented aberrant miRNA levels in colorectal cancer, with some
miRNAs reported to actively regulate tumorigenesis. A recurrent
phenomenon with miRNAs is their frequent participation in feedback
loops, which probably serve to reinforce or magnify biological
outcomes to manifest a particular cellular phenotype. Here, we
review the roles of oncogenic miRNAs (oncomiRs), tumor
suppressive miRNAs (anti-oncomiRs) and miRNA regulators in
colorectal cancer. Given their stability in patient-derived samples
and ease of detection with standard and novel techniques, we also
discuss the potential use of miRNAs as biomarkers in the diagnosis of
colorectal cancer and as prognostic indicators of this disease.
MiRNAs also represent attractive candidates for targeted therapies
because their function can be manipulated through the use of
synthetic antagonists and miRNA mimics.
KEY WORDS: Cancer, Colon, Colorectal, Rectal, Tumorigenesis,
microRNA
Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer-
related deaths worldwide (McGuire, 2016) and the second leading
cause of cancer-related deaths in the USA (https://www.cdc.gov/
cancer/colorectal/). Most cases of CRC are sporadic, although
20-30% of affected individuals carry inherited mutations (Da Silva
et al., 2016; Hahn et al., 2016). CRC is generally classified into
five stages, 0 to IV, characterized by submucosal invasion (stage
I), penetration of the outer colonic wall (II), lymph node invasion
(III) and metastasis (IV). The morphological changes and major
mutations (in key tumor suppressor genes such as APC and TP53)
that are involved in the formation of pre-cancerous lesions (or
adenomas) have been determined via the examination of biopsies
and are thus generally well defined (Fig. 1). The entire process of
CRC tumorigenesis is slow – it is estimated to take nearly two
decades for a tumor to develop (Jones et al., 2008) – and
endoscopy has proven to be effective for early detection and
removal of adenomas and tumors (Rabeneck et al., 2010). Death
rates from colorectal cancer have declined over the past 20 years,
largely thanks to early detection; however, CRC incidence still
remains high (Siegel et al., 2015) and new treatments have been
lagging. Treatment usually entails surgical removal of tumors,
which may be followed with chemotherapy and/or targeted
biologics for stage III and IV tumors (Graham and Cassidy,
2012). New drugs that have recently been approved are primarily
biologics that target tumor angiogenesis (VEGF, the vascular
endothelial growth factor and its receptor, VEGFR) or the
epidermal growth factor receptor (EGFR, see Glossary, Box 1)
(Köhne, 2014). However, these drugs have had limited success,
and in the case of EGFR inhibitors, oncogenic mutations in KRAS
(occurring in about 40% of CRCs) confer resistance (Gong et al.,
2016). Therapies targeting microRNAs (miRNAs) or their
pathways may provide new or complementary targets for
therapeutic and preventative applications.
MiRNAs are small, single-stranded RNAs of 21-23 nucleotides
(nt) in length that repress mRNA translation and trigger mRNA
degradation (Lin and Gregory, 2015; Towler et al., 2015). Their
biogenesis involves several steps (see Box 2) and their functions can
be post-transcriptionally modulated via the regulation of their
biogenesis, interaction with targets, degradation and sequestration
from other mRNAs (Ha and Kim, 2014). Defects in miRNA
processing often appear to be associated with tumorigenesis
(Lambertz et al., 2010; Sekine et al., 2009). These studies suggest
that, in the context of global miRNA depletion, the loss of tumor-
suppressive miRNAs (known as anti-oncomiRs) may have a greater
effect on driving tumorigenesis than does the depletion of
oncogenic miRNAs (known as oncomiRs). This phenomenon is
particularly evident in mouse studies that have investigated the
consequences of inactivating Dicer1 (Lambertz et al., 2010; Sekine
et al., 2009), which is required for the processing of almost all
miRNAs (see Boxes 1 and 2). Human DICER1 also appears to have
a tumor-suppressive role in CRC cell lines (Iliou et al., 2014), and in
other cancers, suggesting that miRNA biogenesis is essential for
repressing tumorigenesis.
In this Review, we expand on the most salient evidence linking
individual miRNAs to the etiology of CRC, with a focus on the
interaction of miRNAs with known oncogenic drivers and
pathways. Information on direct targets of key miRNAs is listed
in Table 1. Relationships among miRNAs and genes known to be
involved in the initiation and progression of CRC are illustrated in
Fig. 2. Genes highlighted are frequently inactivated (APC,
TGFBR2, TP53, SMAD4, PTEN), constitutively activated (KRAS)
or overexpressed (MYC) in CRC (Cancer Genome Atlas Network,
2012; Guinney et al., 2015). In CRC, the miRNA-mediated
modulation of these genes has been found to regulate features of
cellular transformation, while many miRNAs also function
downstream of these factors. We will explore these relationships,
and others that implicate miRNAs as critical modulators of CRC
pathobiology and as potential therapeutic targets.
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miRNA regulation of intestinal stem cells and CRC tumor-
initiating cells
Several miRNA and miRNA pathways have been found to regulate
normal intestinal epithelial stem cells (IESCs) in the mouse gut.
IESCs are needed for replenishing epithelial cells, which are
constantly turning over, much like skin cells. Cancer ‘stem cells’, by
contrast, are defined by their tumor-initiating potential, and thus,
may also be called tumor-initiating cells (TICs) – a nomenclaturewe
will use for clarity. TICs typically exhibit frequent resistance to
chemotherapeutic drugs, and have often undergone an epithelial-to-
mesenchymal transition (EMT; see Glossary, Box 1) (Singh and
Settleman, 2010). Dicer (Iliou et al., 2014) and multiple miRNAs
[including, miR-34a (Bu et al., 2013, 2016), miR-106b (Zheng
et al., 2015a), miR-140 (Zhai et al., 2015), miR-146a (Hwang et al.,
2014), miR-183 (Wellner et al., 2009), miR-200 (Wellner et al.,
2009), miR-203 (Wellner et al., 2009), miR-215 (Jones et al., 2015),
miR-302b (Zhu et al., 2012), miR-328 (Xu et al., 2012b), miR-363
(Tsuji et al., 2014), miR-371 (Li et al., 2015c) and miR-451 (Bitarte
et al., 2011)] reportedly regulate CRC TICs. As part of a positive-
feedback loop (a recurring phenomenon with miRNAs in cancer),
the E-box transcription factor and inducer of EMT, SNAIL,
promotes β-catenin-mediated transcription of miR-146a (Hwang
et al., 2014). β-catenin acts in the nucleus as a transcriptional co-
activator with DNA-binding transcription factors from the TCF/
LEF family, most frequently as a downstream mediator of Wnt
signaling (MacDonald et al., 2009). This activation of miR-146
promotes symmetric division of TICs by targeting and inhibiting
NUMB, a protein that negatively regulates Notch (see Glossary,
Box 2) and the stability of β-catenin (Hwang et al., 2014).
Symmetric stem cell division occurs when one stem cell creates two
daughter stem cells, whereas asymmetric division generates one
stem cell and one progenitor committed to differentiation, although
with cancer, such ‘progenitors’ do not necessarily differentiate, but
instead lack tumor-initiating properties (Meacham and Morrison,
2013). Thus, symmetric divisions of TICs produce more cells that
are capable of initiating new tumors and that may be more resistant
to chemotherapeutic drugs. Interfering with this regulatory loop not
only reduces symmetric divisions (and promotes asymmetric
divisions) of CRC TICs, but also restores the susceptibility of
cancer cells to cetuximab, an inhibitor of EGFR that is used to treat
CRC (Hwang et al., 2014).
Conversely, miR-215, which is transcriptionally activated by the
intestinal-specific transcription factor CDX1, appears to repress
stem cell markers and is significantly depleted in CRC TICs (Jones
et al., 2015). MiR-215 (and the related miR-192), functions in part
by regulating cell cycle genes and by repressing cell proliferation
(Boni et al., 2010; Fesler et al., 2015; Jones et al., 2015). This is
consistent with the prognostic features of miR-192 (Chiang et al.,
2012) andmiR-215 (Karaayvaz et al., 2011; Faltejskova et al., 2012;
Chiang et al., 2012; Li et al., 2013b), which are both depleted in
CRC tumors.
Less is known about the regulation of normal intestinal stem
cells by miRNAs. Nonetheless, recent studies have demonstrated
that both miR-34a and Let-7 (see Glossary, Box 1) miRNAs
appear to repress stem cell fate in the gut (Bu et al., 2016;
Madison et al., 2015). Like miR-146, miR-34a modulates stem
cell fate through the inhibition of NUMB [which inhibits Notch, a
positive regulator of IESC fate (Pellegrinet et al., 2011)], although
miR-34a inhibits symmetric stem cell division, probably because
of its effects on an additional target of miR-34a, Notch1 (Bu et al.,
2016). It is also worth noting that miR-34a represses IESC fate
only in response to inflammatory signals (Bu et al., 2016),
elaborated further below. Inhibiting miRNAs that promote TIC


























Fig. 1. Step-wise tumorigenesis in colorectal cancer. Cartoon of the large intestine showing the structure of the normal colonic mucosa, with many mucous-
secreting goblet cells (blue) at top left. Tumorigenesis begins with the mutation of intestinal epithelial stem cells (shown in magenta) in the colon or rectal mucosa,
with mutations often occurring first in the APC, KRAS or BRAF genes. Mutations in BRAF or KRAS (in the absence of Wnt pathway mutations) are often
associated with the formation of aberrant crypt foci (ACF). Most adenomas are associated with mutations inWnt pathway components, such as APC orCTNNB1,
which result in hyperactivation of Wnt signaling in early adenomas. Deregulation of Wnt signaling often co-occurs with mutations in KRAS, PIK3CA, or
other mutations, leading to activation of the PI3K-Akt signaling cascade. Adenomas then progress with additional mutations (e.g. SMAD4) and frequently acquire
genomic instability. Lastly, mutations in TP53 and TGFBR2 are associated with later stages of cellular transformation and with invasive characteristics of
adenocarcinomas. Official human gene symbols and full names:AKT, AKT serine/threonine kinase 1;APC, adenomatous polyposis coli orWnt signaling pathway
regulator; BRAF, B-Raf proto-oncogene, serine/threonine kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog or proto-oncogene and GTPase; PIK3CA,
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; SMAD4, Mothers against decapentaplegic homolog family member 4; TGFBR2,
transforming growth factor beta receptor 2; TP53, tumor protein p53.
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cell population or for conferring therapeutic sensitization, although
deleterious effects on the normal IESC population must be
avoided. Moreover, the possible plasticity of cellular identity may
render TICs as an ever-moving target (Meacham and Morrison,
2013), complicating the elimination of a specific TIC lineage.
Examples of how miRNAs regulate CRC TICs are shown in
Fig. 3.
Regulators of miRNA biogenesis (see Box 2) can also modulate
stem cell function and tumorigenesis. This is observed for the RNA-
binding proteins LIN28A and LIN28B, which directly repress the
biogenesis of Let-7miRNAs. As discussed inmore detail later in this
Review, LIN28 proteins appear to play an oncogenic role in many
cancer types (Viswanathan et al., 2009), including CRC (King et al.,
2011a,b). Several reports, including our own, have documented the
pro-tumorigenic effects of LIN28 proteins on the initiation and
progression of intestinal tumorigenesis in mouse models (Madison
et al., 2013; Tu et al., 2015). LIN28B also augments intestinal
organoid colony-forming potential, which is a stem cell phenotype
(Madison et al., 2013). This suggests that LIN28B enhances, while
Let-7 represses, IESC fate, symmetric division or survival.
Spontaneous tumors in transgenic mice that overexpress LIN28 in
the intestine also exhibit hyperactivation of the Wnt signaling
pathway (Madison et al., 2013; Tu et al., 2015). These oncogenic
effectswere found to be largely due to theLIN28-mediated depletion
of Let-7 miRNAs (Madison et al., 2013; Tu et al., 2015).
Thus, miRNAs can interact with known stem cell signaling
pathways, such as Notch and Wnt, to augment stem cell fate or
proliferation, which could contribute to development of CRC. The
direct targets and relevantmediators downstreamofmiR-146 andmiR-
34a implicate the Notch andWnt signaling pathways, while regulators
remain to be delineated downstream of Let-7, excepting recent insights
into a Let-7 target, Hmga2, which is discussed later in this Review.
MicroRNA interactions with knownmolecular drivers of CRC
Known drivers of CRC have been identified through large-scale
cancer genome sequencing efforts (Cancer Genome Atlas Network,
Box 1. Glossary of selected terms and genes/proteins involved in CRC
Argonaute (Ago): A protein that is a critical component of the RNA-induced silencing complex (RISC) that mediates inhibitory effects on mRNA translation
by miRNAs. Four Ago proteins have been characterized in mammals (AGO1-AGO4), which all appear capable of functioning to target and silence mRNAs
via miRNAs and the RISC.
CTNNB1:Gene that encodes β-catenin, a transcriptional effector inWnt signaling that binds and interacts with the DNA-binding transcription factors TCF4 and
LEF1. β-catenin also binds to the intracellular domain of E-cadherin at adherens junctions, distinct from its role in Wnt signaling.
Dextran sulfate sodium (DSS)-induced colitis model: DSS oral administration to mice causes intestinal epithelial damage and cell death, leading to a
compromised barrier and severe inflammation. This inflammation resembles human ulcerative colitis (UC), with increases of pro-inflammatory cytokines, such
as TNFα, IL-1α/β, IL-6 and IL-18 (Chassaing et al., 2014).
Dicer: An RNase III family enzyme capable of cleaving double-stranded RNA. This enzyme catalyzes the second cleavage event during miRNA biogenesis
whereby it cleaves the pre-miRNA ‘hairpin’ structure near the terminal loop region, to remove this structure to generate a double-stranded miRNA.
Digital PCR: An approach for the precise nucleic acid quantification by directly counting the total number of target molecules through multiplexed nanoliter-
sized reactions.
Epithelial-to-mesenchymal transition (EMT): The morphological and phenotypic change of an epithelial cell into a fibroblast-like cell. This process
appears necessary for the migration of an epithelial-derived cancer through the basement membrane, into and out of the vasculature, culminating in the
metastasis of malignant cells to distant organs.
Fecal occult blood test (FOBT): Assay used to detect occult blood in stool samples that may indicate the presence of colorectal polyps or cancer.
Hypermutated colorectal cancers: This category of CRCs account for about 15% of all cases and is characterized by a high rate of mutations (>12 per 106
bases or >180 per exome), microsatellite instability (MSI), and defects in DNA mismatch repair. However, these cancers typically possess a stable diploid
genome and lack large chromosomal translocations and deletions (Cancer Genome Atlas Network, 2012; Guinney et al., 2015).
IL-6/STAT3 signaling: IL-6 is a pro-inflammatory cytokine produced by T-cells and macrophages in response to infection or tissue damage. Through the
IL6R-GP130 heterodimeric receptor, and associated Janus-associated kinase (JAK) proteins, IL-6 activates the transcription factor STAT3, which triggers
the transcription of genes involved in the acute phase response, such as C-reactive protein, serum amyloid A, and fibrinogen. Activation of the IL-6/STAT3
signaling cascade is a driver of tumorigenesis through effects on the intestinal epithelium by enhancing cell survival and proliferation (Quante et al., 2013).
Cancer associated fibroblasts in CRC are also a source of IL-6 (Huynh et al., 2016).
Let-7: Let-7 miRNAs comprise one of the largest miRNA families in mammals, with 12 genes encoding 8 unique miRNAs (Kamanu et al., 2013). The Let-7
miRNA family is implicated in maintaining differentiation and preventing tumorigenesis across multiple tissue types (Takamizawa et al., 2004; Johnson
et al., 2007; Sampson et al., 2007; Shell et al., 2007; Boyerinas et al., 2008).
Lipopolysaccharide (LPS): Largemolecule found in the outer membrane of gram-negative bacteria consisting of a polysaccharide unit covalently linked to
a disaccharide that is linked to multiple fatty acids. LPS is highly immunogenic endotoxin that binds to and activates the Toll-like receptor 4 (TLR4).
MET (mesenchymal-to-epithelial transition): The morphological and phenotypic change of a fibroblast-like cell into a epithelial cell. This process appears
necessary for metastasis to distal organs, although the role of such a process in CRC metastasis remains to be fully characterized.
NF-κB(NFΚB):A transcription factor formedbyhomodimersandheterodimersof fivegeneproducts that isactivateddownstreamof stressors (free radicals), pro-
inflammatory cytokines (such asTNFα, IL-1, and LT-β), andmicrobial products (viaToll-like receptors). The activation of NFΚB represses apoptosis (Kucharczak
et al., 2003), regulates the immune responses in the gut (Wullaert et al., 2011) and plays a role in fueling CRC tumorigenesis (Ben-Neriah and Karin, 2011;
Vaiopoulos et al., 2013).
Notch signaling in the intestine: The NOTCH1 and NOTCH2 transmembrane receptors are expressed in the IESCs and transmit signals from Notch
ligands, such as DLL1, DLL4 and JAG1 (expressed in adjacent cells). Notch signaling is required to maintain stem cell fate and proliferation in the intestine
(Pellegrinet et al., 2011), and is frequently activated in CRC (Chu et al., 2011; Rodilla et al., 2009).
NUMB: Amembrane-localized protein asymmetrically distributed following stem cell division that plays an important role negatively regulating Notch. It also
can destabilize β-catenin in a Notch-dependent, but Notch ligand-independent manner (Kwon et al., 2011).
PGE2 (prostaglandin E2): A pro-inflammatory prostaglandin that binds to the EP2 and EP4 receptors on T cells, dendritic cells, and intestinal epithelial
cells (Dorsam and Gutkind, 2007). PGE2 can activate Wnt signaling and the KRAS-MAPK signaling cascade through SRC (Buchanan and DuBois, 2006),
with phenotypic augmentation of angiogenesis, tumor proliferation, and metastasis (Dorsam and Gutkind, 2007).
TNFα (tumor necrosis factor alpha): A pro-inflammatory cytokine produced by activated macrophages, dendritic cells, and T cells, most frequently
downstream of TLR activation. TNFα is a major contributer to the pathogenesis of inflammatory bowel disease, and stimulates angiogenesis, the production
of other pro-inflammatory cytokines, and can trigger intestinal epithelial cell death.
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2012; Guinney et al., 2015) and include frequent oncogenic
mutations in KRAS, BRAF and TP53, which are also common in
other cancer types, such as melanoma (Krauthammer et al., 2012),
and malignancies of the lung (Cancer Genome Atlas Research
Network, 2014) and pancreas (Bailey et al., 2016). However, the
hallmark feature of CRC is the hyperactivation of the Wnt pathway,
usually caused by mutations in the tumor suppressor gene APC.
Below, we discuss the interaction of miRNAswith genes commonly
mutated in CRC, beginning with the relationships of miRNAs with
Wnt pathway regulators.
Wnt signaling modulation by miRNAs
The deregulation of Wnt signaling is the most frequent molecular
aberration in CRC, with inactivating mutations in the APC gene
occurring in ∼75% of all tumors (Cancer Genome Atlas Network,
2012; Guinney et al., 2015). APC encodes a large scaffolding
protein that is part of the AXIN destruction complex, which is
necessary for the phosphorylation and degradation of β-catenin
(MacDonald et al., 2009). Loss of APC function results in increased
levels of β-catenin, a key effector of Wnt signaling that interacts
with the HMG-box DNA-binding factor TCF4 (TCF7L2) to drive
target gene transcription. Activating mutations in CTNNB1 (β-
catenin; see Glossary, Box 1), or in other Wnt signaling activators
(e.g. RSPO2/3) (Morin et al., 1997; Seshagiri et al., 2012) can also
hyperactivate Wnt signaling in CRC, as can inactivating mutations
in Wnt repressors (e.g. AXIN2, SFRP1, RNF43 or ZNRF3) (Liu
et al., 2000; Suzuki et al., 2004; Koo et al., 2012). Alternatively,
miRNAs can also modulate Wnt signaling through the repression of
pathway components. For example, miR-135a/b miRNAs, which
are overexpressed in CRC, are able to directly target APC, leading to
the upregulation of Wnt signaling (Nagel et al., 2008). MiR-135a/b
is also predicted to target and inhibit secreted frizzled-related
protein 4 (SFRP4), which binds and represses extracellular Wnt
proteins (Kawano and Kypta, 2003). SFRP4 and miR-135
expression is inversely correlated in multiple types of cancer
(Jacobsen et al., 2013). In a likely positive feedback loop, miR-135b
is transcriptionally activated by TCF4/β-catenin, and is dramatically
increased in colonic tumors in mice with inactivated Apc and in
sporadic human CRC (Valeri et al., 2014). In mice, mutations in the
canonical CRC tumor suppressors Pten or Trp53 in the context of
Apc loss greatly enhance the upregulation of miR-135b, with
phosphoinositide 3-kinase (PI3K) and downstream FOXO1 and
FOXO3A transcription factors confirmed as regulators of miR-135b
(Valeri et al., 2014). The mechanism of TP53-mediated repression
of miR-135b, however, has yet to be explored. In addition, given
that the inhibition of miR-135b by specific antagomiRs greatly
represses tumorigenesis in multiple mouse models (Lin et al., 2013;
Valeri et al., 2014), miR-135b might drive tumorigenesis by
inhibiting multiple tumor suppressors (besides APC), such as
TGFBR2 (Valeri et al., 2014). Known relationships between
canonical Wnt signaling and miRNAs are illustrated in Fig. 3.
Also operating upstream of Wnt, the miR-34 family (miR-34a/
b/c) directly targets and represses multiple effectors of Wnt
signaling, including WNT1, WNT3, LRP6 (a Wnt ligand co-
receptor), β-catenin and LEF1 (an HMG-box transcription factor
that, like TCF4, interacts with β-catenin) (Kim et al., 2011). The
transcription of miR-34 is directly stimulated by TP53, providing
insight into how TP53 can repress Wnt signaling (Kim et al.,
2011). This relationship might be integral to the tumor-suppressive
properties of miR-34 miRNAs; the negative regulation of Wnt
signaling might also mediate miR-34-driven repression of
intestinal stem cell fate (see below). Additional inhibitors of
Wnt ligands, or β-catenin-mediated function, include miR-29b,
miR-29c, and miR-93, which target BCL9L [a β-catenin co-
activator and miR-29b target (Subramanian et al., 2014; Zhang
et al., 2014b; Tang et al., 2015)], GNA13 and PTP4A [miR-29c
targets that negatively regulate GSK3β (Zhang et al., 2014b), a
kinase that phosphorylates β-catenin and triggers degradation] and
SMAD7 [a miR-93 target that promotes nuclear accumulation of
β-catenin (Subramanian et al., 2014; Zhang et al., 2014b; Tang
et al., 2015)]. Although the precise mechanism is not known, miR-
21 can also enhance TCF4/β-catenin-mediated transcriptional
activation of surrogate reporters (i.e. TOPFLASH) and
endogenous target genes. This miR-21 activity is coincident
with, and dependent on, β-catenin phosphorylation at Ser552 (Lin
et al., 2014). In another example of a potential positive feedback
loop, miR-21 might be directly activated by TCF4/β-catenin. This

































The biogenesis of miRNAs begins with the RNA polymerase II-mediated
transcription of RNAs that are capped and polyadenylated. These
primary miRNAs (pri-miRNAs) then undergo cleavage by the
microprocessor complex (consisting of the RNase III nuclease Drosha
and RNA-binding protein DGCR8) to generate short hairpin-shaped
structures of 60-90 nucleotides (nt), called pre-miRNAs. These pre-
miRNAs are exported from the nucleus by Ran/exportin-5 in a GTP-
dependent manner to then be further processed in the cytoplasm by
Dicer, also an RNase III nuclease, to generate 21-23 nt double-stranded
miRNAs. MiRNAs are then loaded into a functional RNA-induced
silencing complex (RISC) with an Argonaute (Ago) protein (e.g. AGO2)
(see Glossary, Box 1). During this loading, a process called strand
selection segregates the ‘guide’ strand (or miR, in red) from the
‘passenger’ (or miR*, in blue) strand. Within the RISC, the guide strand
base pairs with complimentary sequences in the 3′UTRof target mRNAs,
usually at positions 2-8 in the miRNA (the seed sequence). This
interaction then triggers the repression of translation and ultimate
degradation of the target mRNA. When investigators state that miRNAs
directly inhibit a target, this refers to the repressive action of amiRNA on a
specific mRNA via the RISC.
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verified in CRC References
OncomiRs elevated in CRC
miR-21 miR-21 LYRM7, POLR3B, PDCD4, ZNF10,
IRAK1BP1, CCDC121, ANKRD46
CDC25A, MSH2, MSH6, PDCD4,
RHOB, PTEN, CCL20, ITGB4
(Chang et al., 2011; Ferraro et al., 2014; Liu et al.,
2011; Peacock et al., 2014; Sheng et al., 2016;
Valeri et al., 2010a; Vicinus et al., 2012; Wang






FYCO1, ZBTB4, EFCAB14, ZNFX1,
CYBRD1, CTSA, ARHGAP1, PTEN
P130 (RBL2), CDC42, PTEN,
HIF1A, CYP7B1, GABBR1,
TGFBR2, VEGFA, PRRX1, DLC1,
CDKN1A, BNIP2, SMAD4, SMAD7
(Chai et al., 2011; Cheng et al., 2016; Fang et al.,
2014; Humphreys et al., 2014; Longqiu et al.,
2016; Ma et al., 2016, 2012; Sokolova et al.,
2015; Tang et al., 2015; Xi et al., 2016; Zhang
et al., 2015a; Zheng et al., 2015a,b; Zhu et al.,
2014 a)
miR-155 miR-155 SH3D19, KDM5B, KIF3A, ZMYM2,
USP30, IGF2, DET1
E2F2, MSH2, MSH6, MLH1, PTEN,
SOCS1




SPIN1, RABGAP1, COPS8, PIGH,
WNT3, ST13, ACTC1, RPAIN
NUMB, CASR (Fetahu et al., 2016; Hwang et al., 2014)
miR-221 miR-221
miR-222
SNX4, FAM35A, ACADM, SBK1,
RALGAPA1, TSPAN13, MYLIP
CDKN1C, PTEN, RECK, PDLIM2,
ICAM1, ADAM17
(Liu et al., 2014; Qin and Luo, 2014; Sun et al.,
2011a,b; Ueda et al., 2009; Xu et al., 2012a;
Xue et al., 2013)
miR-31 miR-31 STK40, ATP8A1, SNX4, RAB5B,
CHMP7, CLASP2, RSBN1
SATB2, RHOBTB1, RASA1, HIF1AN (Chen et al., 2014d; Kent et al., 2016; Sun et al.,
2013; Xu et al., 2013; Yang et al., 2013)
miR-196 miR-196a
miR-196b
CTSO, MAOA, TMEM30B, PANK2,
SNX24, RASGRP1, NAALADL2,
PLN
Currently unknown (Ge et al., 2014; Schimanski et al., 2009)
miR-25 miR-92a ITM2B, DNAJB9, PPCS, EFR3A,
MSR1, KLF2, MSRB3, PDE1A,
ZFYVE21
PTEN, KLF4, IQGAP2, BIM (Ke et al., 2015; Lv et al., 2016; Pelossof et al.,
2016; Zhang et al., 2014a) (Tsuchida et al.,
2011)
Anti-oncomiRs depleted in CRC
Let-7 7a/b/c/d/e/f/g/
imiR-98
CDC34, HMGA2, IGF2BP1, CCNJ,
IGF2BP2, NR6A1, ARID3B, CCL7




TMEFF1, TAF5, WASF1, LRRC40,
TMEM59L, ZNF551, JAG1, SMAD4
AXL, CD24, SRC, PAR2, AXIN2,
KIT, ZNF281, IL6R, FMNL2, E2F5,
LMTK3, HMGB1, MYC, KITLG
(Chandrasekaran et al., 2016; Hahn et al., 2013;
Jacob et al., 2016; Kim et al., 2013; Kress et al.,
2011; Lu et al., 2015; Ma et al., 2013b;
Mudduluru et al., 2011; Muppala et al., 2013;
Rokavec et al., 2014; Siemens et al., 2013;
Yang et al., 2014)
miR-26 miR-26a
miR-26b
SFXN1, MAPK6, DEPDC1, DPNA2,
CDC6, SULF1, TMEM2, USP9X,
PTEN
PDHX, LIN28B, ZCCHC11, HMGA1,
MYCBP, SETD8, NAMPT
(Chen et al., 2014a; Fu et al., 2014; Zeitels et al.,
2014; Zhang et al., 2013a)
miR-192 miR-192
miR-215
VCAN, MYLK, NOX4, LOXL2,
ZBTB4, BICD2, SPARC, MUM1L1






CRADD, ARSI, SKA1, KANK4,
NEK6, CDC25A, EIF2C2, AP1AR
HOXD10, KLF4, MCL1, BCLW, IL6R,
MTOR, RAP1B
(Gong et al., 2013; Li et al., 2015a; Peng et al.,




RRM2, KIF11, MYBL2, AVEN, TDG,
CDC7, MEX3B, SEC23A, FAP,
PGM3, LOX, GSKIP, TXNDC5
DTL, PIK3CD, IRS2, KRAS, BCL2,
SIX1, ADAM19, HELZ, PIK3C2A
(Baraniskin et al., 2012; Liao et al., 2014;
Schepeler et al., 2012; Zhang et al., 2015b,c;
Zhao et al., 2014; Zhong et al., 2013)
miR-25 miR-25 ITM2B, DNAJB9, ZFYVE21, EFR3A,
MSR1, KLF2, MSRB3, PDE1A





TDG, TAF11, NREP, TET1, CHSY1,
MEX3B, EIF4E2, PPM1D, PTEN
KLF4, TIAM1, TCF7L2, SNAIL,
BCL9L, LRP6, IGF1, GNAI13,
PTP4A
(Li et al., 2016b; Patel and Gooderham, 2015;
Subramanian et al., 2014; Tang et al., 2014a;





FAP, ZEB1, ZEB2, SEC23A, RECK,
ZFPM2, CFL2, SYDE1, LHFP
ZEB1, ZEB2, SIP1, DLC1, SOX2 (Hu et al., 2010; Lu et al., 2014; Tian et al., 2014;




MYLK, RECK, FGF7, SPRYD3,
PLSCR4, RUNX1T1, ISLR, FAT4,
SVEP1, ARL2, HMGA1, HMGA2
AP4, PTGS2, MYB, VEGFR2, BCL2,
CARMA3, RAF1, UPC2, COPS2,
MTSS1, KL
(de Groen et al., 2015; Li et al., 2016a; Liu et al.,
2010; Shi et al., 2014; Wang et al., 2014b; Yang
et al., 2015; Yang et al., 2016; Ye et al., 2016;
Young et al., 2012)
miR-483 miR-483-5p PSMB9, HSH2D, IFIT3, ALCAM,
ASRGL1, ASPN, CUTA, CLCN3
CKB (Loo et al., 2015)
miR-483-3p LY86, IKZF1, ICAM1, SGMS2,
MAPKAPK2, WDR44, ZBTB7B
DLC1 (Cui et al., 2016; Li et al., 2014c)
*These targets are computationally predicted (by TargetScan and miRanda) and are not necessarily experimentally verified.
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possibility is based on the identification of TCF4 binding sites
near miRNA transcriptional start sites, with confirmation of
binding via chromatin immunoprecipitation (ChIP) and qPCR in
CRC cell lines (Lan et al., 2012). The pro-oncogenic miRNA,
miR-155, might also enhance Wnt/β-catenin signaling by directly
targeting and inhibiting HMGB1, which has to date only been
reported as a factor that promotes Wnt signaling (Itou et al., 2011;
Zhou et al., 2012; Wan et al., 2016).
In summary, many miRNAs act as regulators of the Wnt pathway
at multiple levels of the signaling cascade, and some miRNAs, such
as miR-34, are capable of restraining both Wnt and Notch signaling
pathways. Wnt-modulating miRNAs deserve particular scrutiny as
potential therapeutic targets given that the Wnt pathway is a central
oncogenic driver of CRC. However, additional mutations in genes
such as KRAS and BRAF are also required in CRC, indicating that
multiple pathways are therapeutically relevant.
miRNA modulation of the small GTPases KRAS and BRAF
Nearly half of all CRC tumors have activating mutations in either of
the small GTPases, KRAS and BRAF, which activate the MAP
kinase (MAPK) pathway and stimulate cell proliferation (Cancer
Genome Atlas Network, 2012; Guinney et al., 2015). Although
studies of some cancers, such as lung and breast cancer, have
demonstrated that Let-7 miRNAs directly repress KRAS mRNA
(Esquela-Kerscher et al., 2008; Iliopoulos et al., 2009; Johnson
et al., 2005), KRAS has not been found to be a Let-7 target in studies
of CRC (King et al., 2011b; Madison et al., 2013, 2015). In contrast
to Let-7, miR-31 appears to be a potent stimulator of KRAS in CRC,
via negative regulation of RASA1, an inhibitor of KRAS function
(Kent et al., 2016; Sun et al., 2013).
The BRAF oncogene is frequently mutated in tumors located in
the proximal colon and is implicated in driving microsatellite
instability (MSI) colon cancers (Domingo et al., 2004). MSI colon
cancers are hypermutated (see Glossary, Box 1), probably as a result
of methylation or mutation of the MLH1, MSH2 or MSH6 genes,
which encode proteins necessary for DNA mismatch repair
(Richman, 2015). Although BRAF has not been shown to have a
direct relationship with many miRNAs, one report has characterized
BRAF mRNA as a target of the miR-378 anti-oncomiR in CRC
(Wang et al., 2015c). More frequently, high miR-31 expression is
associated with BRAF mutations and an aggressive cancer
phenotype (Ito et al., 2014; Nosho et al., 2014; Choi et al., 2016).
However, our present understanding of the molecular function of
miR-31 is limited, although this oncomiR is reported to be
transcriptionally activated downstream of the KRAS-BRAF-
MAPK signaling cascade (Kent et al., 2016).
The miR-34 anti-oncomiR family and TP53
The miR-34 family consists of miR-34a, transcribed at one locus,





































Fig. 2. Genes frequently mutated in colorectal cancer and their relationships with miRNAs. Genes frequently mutated in CRC (highlighted in orange)
regulate and are regulated by miRNAs. Oncogenic miRNAs are depicted in blue, tumor-suppressive miRNAs in red, and miRNAs with reported pleiotropic effects
in purple. Direct relationships are shown with solid lines, while indirect relationships are illustrated with dotted lines. TheWnt pathway is augmented by miR-135b,
miR-21 and miR-155, and inhibited by miR-34a, miR-29b/c. Downstream of Wnt, MYC transcriptionally activates the miR-17-92 locus, but represses expression
of miR-15, miR-26 and miR-30. KRAS augments expression of miR-31. MYC and KRAS promote cell cycle progression (CC, circular arrows). In the PI3K
pathway, which is negatively regulated by PTEN, miR-135b is augmented by PI3K inhibition of FoxO transcription factors (FOXO1 and FOXO3A), which
represses cell cycle progression. MiR-221, miR-21 and miR-17/106 enhance activation of PI3K signaling by repressing negative regulators of this pathway.
MiRNAs also modulate inflammatory pathways mediated by the transcription factors NFΚB and STAT3 by directly inhibiting IL-6 (via Let-7 miRNAs, which are
inhibited by LIN28B) or the IL-6 receptor (via miR-34 and miR-125b). MiR-221/222 and miR-29b/c can also augment this pathway via indirect stimulatory effects
on IL-6, NFΚB, and STAT3. The TGF-β pathway, which is important for repressing cellular proliferation and cell cycle progression is also antagonized by several
miRNAs, including miR-17/106, miR-135b, and miR-20a through effects on TGFBR2 and SMAD4. The miRNA miR-93 can stimulate the TGF-β pathway by
repressing the inhibitory SMAD7, although the effect of miR-93 is inhibitory of Wnt signaling through inhibition of SMAD7, which can augment nuclear
accumulation of β-catenin. Lastly, several miRNAs have effects on EMT in CRC tumorigenesis, with miR-15/16 and miR-34 (which are transcriptionally activated
by TP53) inhibiting this process, while miR-21 enhances EMT. References for the effects of these miRNAs can be found in Table 1 or in the main text. Official
human gene symbols and full names: APC, adenomatous polyposis coli or WNT signaling pathway regulator; CTNNB1, β-catenin; MYC, v-myc avian
myelocytomatosis viral oncogene homolog; KRAS, Kirsten rat sarcoma viral oncogene homolog or proto-oncogene and GTPase; PI3K, phosphatidylinositol-4,5-
bisphosphate 3-kinase (PIK3CA, PIK3CB, PIK3CD, PIK3CG); PTEN, phosphatase and tensin homolog; FoxO, forkhead box O1 and O3a (FOXO1 and
FOXO3A); PDCD4, programmed cell death 4 (neoplastic transformation inhibitor); LIN28B, lineage-28 homolog B; NFΚB, nuclear factor kappa B (NFKB1,
NFKB2, REL, RELA, RELB); IL6, interleukin 6; IL6R, interleukin 6 receptor; STAT3, signal transducer and activator of transcription 3; TGFBR2, transforming
growth factor beta receptor 2; SMAD4, mothers against decapentaplegic homolog family member 4; SMAD7, mothers against decapentaplegic homolog family
member 7; TP53, tumor protein p53.
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miRNAs regulate mRNAs involved in the cell cycle (Ebner and
Selbach, 2014), growth (Kress et al., 2011), DNA damage (Takeda
and Venkitaraman, 2015) and apoptosis (Ebner and Selbach, 2014);
these interactions are likely to be associated with the tumor-
suppressive properties of miR-34 miRNAs and their ability to
induce apoptosis and senescence (Tazawa et al., 2007). The miR-
34a and the miR-34b/c loci are direct transcriptional targets of the
TP53 tumor suppressor (Chang et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007), the levels of which, in
turn, are indirectly augmented bymiR-34. This positive feedback on
TP53 is likely to be due to several mechanisms. First, miR-34
directly represses Mdm4 (HDM4 in humans), which encodes a
RING-finger protein that binds to TP53 and blocks its ability to
activate target genes (Okada et al., 2014). Second, miR-34 promotes
modest (and probably indirect) stimulation of the TP53 promoter
(Gao et al., 2015). Independent of TP53, miR-34 is induced by
FOXO3A (forkhead box O3a transcription factor) in a feedback
loop involving MK5 and MYC. MK5 is a MYC target gene that
encodes a kinase that phosphorylates and activates FOXO3A, which
then directly activates the expression of the miR-34b/c promoter
(Kress et al., 2011). MK5 is downregulated in CRC, and is
associated with reduced survival in CRC patients (Kress et al.,
2011). Thus, both MYC and TP53 can promote miR-34 expression.
Another key role for miR-34a in CRC is the regulation of IL-6/
STAT3 signaling (see Glossary, Box 1), which fuels EMT and
metastasis in CRC (Rokavec et al., 2014). In this pathway, STAT3
directly represses the transcription of miR-34a, which in turn,
directly represses the IL-6 receptor (IL6R), thus forming a positive
feedback loop (Rokavec et al., 2014) (Fig. 2). Using cell culture
models and inflammatory bowel disease (IBD) mouse models,
Rokavec et al. (2014) revealed that miR-34a is key for the repression
of tumor migration, invasion and metastasis via repression of the IL-
6/STAT3 signaling pathway. Studies using cultured human CRC
cells (Bu et al., 2013) and mouse models (Bu et al., 2016) indicate
that miR-34 also regulates IESC and CRC stem cell division.
Relevant to IESC, the epithelial inactivation of miR-34a does little
to perturb stem cell proliferation in the mouse intestine (Bu et al.,
2016). However, in the context of inflammatory stimuli [i.e. DSS
(dextran sulfate sodium)-induced colitis mouse models or in
response to TNFα treatment; see Glossary, Box 1], the loss of
miR-34a enhances symmetric IESC division (Bu et al., 2016).
Interestingly, TP53 has a similar effect; in mouse models,
inactivation of Trp53 (the mouse homologue) enhances IESC
competition and clonal expansion exclusively in the context of
inflammation (Vermeulen et al., 2013). Likewise, in humans, an
inflammatory microenvironment enables mutations in TP53 to
accelerate clonal expansion of pre-cancerous lesions, promote
tumor growth and fuel cancer progression in CRC (Brentnall et al.,
1994; Leedham et al., 2009).
Thus, although miR-34a may not be required for TP53 function
in the context of normal TP53 dosage (Okada et al., 2014), miR-34a
deficiency appears to augment CRC tumorigenesis when TP53
is haploinsufficient. Aside from acting as an effector of TP53,
miR-34a expression downstream of the canonical oncogenic
transcription factors, MYC and STAT3, described above, provides
negative feedback on tumor cell proliferation, survival and
metastasis, which highlights the multifaceted mechanisms by
which miR-34 represses tumorigenesis. The connection of miR-
34 with TNFα and IL-6 also highlights the key role of inflammation,
which increases the risk and fuels the progression of CRC (Lasry
et al., 2016).
miR-21 and miR-221/222 in pro-inflammatory signaling
pathways
miR-21 is one of the most prominent oncomiRs in CRC, and has
demonstrated pro-tumorigenic properties in many other solid tumor
types (Pan et al., 2010; Wang et al., 2014c). Repression of the well-
characterized target PDCD4, a tumor suppressor, appears to
mediate the key oncogenic effects of miR-21 (Frankel et al.,
2008). PDCD4 is a pro-inflammatory factor that is activated by
apoptosis stimuli and is required for the lipopolysaccharide (LPS)-
mediated activation of NF-κB (NFΚB) and IL-6 (see Glossary,
Box 1) (Sheedy et al., 2010). PDCD4 can also be repressed by
PGE2 (see Glossary, Box 1), a pro-inflammatory prostaglandin that
also activates Wnt signaling (Buchanan and DuBois, 2006).
COX2, a prostaglandin-endoperoxide synthase, is responsible for
generating PGE2 and is frequently overexpressed in CRC (Sano
et al., 1995). Studies indicate that COX2/PGE2-mediated
repression of PDCD4 occurs via the induction of miR-21
(Peacock et al., 2014). Consistent with this, PDCD4 protein
levels decrease progressively during CRC tumorigenesis, as
normal tissue transforms to adenocarcinoma (Ma et al., 2013a;
Mudduluru et al., 2007) and loss of PDCD4 protein is significantly
associated with reduced patient survival (Mudduluru et al., 2007).
PDCD4 also represses the invasion and intravasation of CRC cell
lines in a chick embryo metastasis model (Asangani et al., 2008);
there is evidence that PDCD4 executes this function by repressing
























Fig. 3. Relationships among miRNAs and canonical Wnt signaling,
metastasis, and tumor-initiating cells. The canonical Wnt signaling pathway
is activated via Wnt and R-spondin interaction with Frizzled (FZD) receptors
together with LRP5/LRP6 co-receptors and LGR4/LGR5 co-activators
(depicted at the top of the figure). This causes inhibition of the APC-Axin-
GSK3β complex, leading to the stabilization of β-catenin, which interacts with
TCF7L2 (previously TCF4; shown in orange). This triggers the transcriptional
activation of target genes. This pathway also enhances a stem cell phenotype
in intestinal epithelial cells and drives metastasis of tumor-initiating cells
(TICs). Several miRNAs directly modulate canonical Wnt signaling or other
effectors, such as NUMB, NOTCH and ASCL2. Oncogenic miRNAs are
depicted in blue, tumor-suppressive miRNAs in red. Direct relationships are
shown with solid lines, indirect relationships with dotted lines. Official human
gene symbols and full names: RSPO1-RSPO4, R-spondin 1-4; FZD1-FZD10,
frizzled class receptor 1-10; LRP5/6, LDL receptor related protein 5/6; LGR4/5,
leucine-rich repeat containing G protein-coupled receptor 4/5; SNAI1, Snail
family transcriptional repressor 1; NUMB, endocytic adaptor protein; APC,
adenomatous polyposis coli or Wnt signaling pathway regulator; AXIN1/2, axin
1/2 ;GSK3B, glycogen synthase kinase 3 beta; TCF7L2, transcription factor 7
like 2 (previously TCF4); CTNNB1, β-catenin; ZEB1, zinc finger E-box binding
homeobox 1; LIN28A and LIN28B, lineage-28; IGF2BP1, insulin-like growth
factor 2 mRNA binding protein 1; HMGA2, high mobility group AT-hook 2;
ASCL2, achaete-scute family bHLH transcription factor 2.
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MiR-21 is also activated downstream of NFΚB and MyD88, an
adapter of Toll-like receptors (TLRs) needed for NFΚB activation
by TLR ligands such as LPS (Kawai et al., 1999). MiR-21 appears
to be integral to the inflammation observed in colitis-associated
colon cancer: in a carcinogen-induced mouse model of CRC using
the mutagen azoxymethane (AOM) plus DSS, genetic inactivation
of miR-21 reduced tumor burden and decreased levels of pro-
inflammatory cytokines (Shi et al., 2015). Loss of miR-21 in
tumors in this model also increased apoptosis and levels of
PDCD4, and reduced levels of activated STAT3 and BCL2
(Shi et al., 2015). This is consistent with a role for PDCD4 in
promoting apoptosis. In addition to PDCD4, the involvement of
other miR-21 targets in tumorigenesis seems likely. In the breast
cancer cell line MCF10A, miR-21 activation (via repression of
PTEN, a PI3K antagonist) appears to be necessary for the optimal
activation of NFΚB, which leads to a positive feedback loop that
activates the expression of IL6 and STAT3, which directly
activates the transcription of miR-21 (Iliopoulos et al., 2010).
Reminiscent of this function of miR-21 in MCF10A, miR-221 and
miR-222 augment NFΚB and STAT3 by indirectly modulating
their protein stability through miR-221/222-mediated direct
inhibition of the nuclear E3 ubiquitin ligase PDLIM2 (Liu et al.,
2014). MiR-221 also targets and inhibits PTEN (Xue et al., 2013)
and the anti-metastatic factor RECK (Qin and Luo, 2014).
Consistent with this, overexpression of miR-221 is associated
with lymph node metastasis of CRC (Hur et al., 2015).
Overall, inflammatory signaling pathways are key drivers of
CRC (Lasry et al., 2016), and miR-21 appears to be a key modulator
of several pro-oncogenic and immunomodulatory factors, such as
PDCD4, NFΚB, and STAT3. Less is known about the involvement
of miR-221/222; however, these miRNAs might also be key
enhancers of NFΚB and STAT3 activation. Repressing the activity
or expression of these miRNAs, especially miR-21, which is
frequently overexpressed in CRC (Slaby et al., 2007; Yamamichi
et al., 2009) and is associated with poor outcomes (Chen et al.,
2016), could represent an effective therapeutic strategy for CRC.
The miR-17 oncomiR family and modulation of TGF-β
signaling
The human miR-17 family consists of eight miRNAs (miR-17,
miR-18a/b, miR-20a/b, miR-93, and miR-106a/b), with three of
these (miR-17, miR-18a, and miR-20a) transcribed from the
miR-17-92 miRNA locus. MiR-17 appears to promote CRC
tumorigenesis, evident in studies showing that it suppresses
apoptosis and cell cycle arrest, increases migration, and drives
tumor xenograft growth of CRC cell lines (Ma et al., 2012). Further
analysis has revealed that miR-17 directly represses the cell cycle
regulator and RB-family member P130 (RB transcriptional co-
repressor like 2, RBL2), a tumor suppressor that also negatively
regulates β-catenin levels andWnt signaling (Ma et al., 2012). MiR-
17 also targets and inhibits PTEN (Fang et al., 2014) and RHOE
(RND3), which encodes a GTP-binding protein (without GTPase
activity) that is reduced in CRC and can repress tumor cell invasion
(Thuault et al., 2016), promote contact inhibition (Hernández-
Sánchez et al., 2015) and downregulate Notch signaling (Tang et al.,
2014b; Zhu et al., 2014b).
Other miR-17 family members are also modulators that fuel
cancer progression. MiR-20a promotes CRC cell line migration,
invasion and the expression of EMTmarkers (Sokolova et al., 2015;
Xu et al., 2015; Cheng et al., 2016). There is evidence that miR-20a
promotes cell cycle progression in response to the multifunctional
cytokine, transforming growth factor beta (TGF-β), a pro-metastasis
but growth-repressive cytokine that represses MYC expression,
induces p21 (CDKN1A), and delays entry into G1/S phase. The
direct repression ofCDKN1A and constituents of a MYC-repressing
complex (consisting of E2F5 and KLF11) by miR-20a were
identified as key interactions contributing to the ability of miR-20a
to neutralize the growth-repressive properties of TGF-β (Sokolova
et al., 2015). MiR-20a abrogation of the growth repression by TGF-
β might enhance the ability of TGF-β to drive migration, invasion
and cancer cell metastasis (Oft et al., 1998).
Like miR-20a, miR-106a/b also appear to enhance metastasis or
an EMT phenotype. MiR-106a targets the TGF-β recteptor
TGFBR2 and is highly expressed in metastatic CRC cell lines,
and promotes cancer cell migration and invasion in vitro (Feng et al.,
2012). TGFBR2 repression might be important for facilitating cell
proliferation early in tumorigenesis, but also later in metastasis to
facilitate a mesenchymal-to-epithelial (MET) transition (see
Glossary, Box 1). Alternatively, and perhaps unexpectedly, given
that TGF-β generally enhances EMT (Oft et al., 1998; Lamouille
et al., 2014), TGFBR2 may repress migration and invasion, as
observed by Feng et al. (2012), although such a role remains to be
functionally dissected. Oddly, miR-106b has been reported to have
both stimulatory (Feng et al., 2012; Zhang et al., 2015a) and
inhibitory (Zheng et al., 2015a) effects on the migration and EMTof
CRC cell lines. In contrast, there are concordant findings that miR-
106b promotes CRC tumor cell metastasis (Feng et al., 2012; Zhang
et al., 2015a; Zheng et al., 2015a), although one study implicated the
anti-metastatic factor DLC1 (Zhang et al., 2015a) as the relevant
miR-106b target, while the other implicated PRRX1 (Zheng et al.,
2015a). The mechanisms underlying the downstream effectors of
miR-106b demand further scrutiny, in light of these disparate
findings.
Further studies are certainly needed to investigate the roles of the
miR-17 family miRNAs in CRC, particularly miR-18a, which is
reported to be elevated in CRC (Song et al., 2011; Wu et al., 2013).
MiR-18a contributes to DNA damage, but can reduce the
proliferation of CRC cell lines and enhance their sensitivity to
apoptotic stimuli (for example, in response to etoposide, a
topoisomerase inhibitor and chemotherapeutic drug) following its
forced expression (Wu et al., 2013; Humphreys et al., 2014). The
contribution of miR-18a to DNA damage and apoptosis is
reportedly due to its direct inhibition of the ATM kinase, which is
required for initiating DNA repair following double-stranded breaks
(Song et al., 2011; Wu et al., 2013). In summary, studies to date
indicate that the miR-17 family fuels CRC metastasis, with
interaction with TGF-β signaling as well as other pathways that
modulate EMT.
The miR-10 anti-oncomiR family
The miR-10 family consists of seven miRNAs (miR-10a/b, miR-
99a/b, miR-100 and miR-125a/b). Most studies of the miR-10
family suggest that these miRNAs possess tumor suppressive
properties (Stadthagen et al., 2013; Chen et al., 2014c; Chen and
Xu, 2015; Li et al., 2015a), although oncogenic function has also
been observed (Nishida et al., 2011, 2012; Wang et al., 2016). In
support of the former role, female Apcminmice develop significantly
more intestinal polyps on a miR-10a knockout background than do
Apcmin mice on a WT background (Stadthagen et al., 2013).
Interestingly, male Apcmin mice do not display this effect. This
sexual dimorphism is possibly due to the observed increase of
lactoperoxidase (LPO), an enzyme that can metabolize estrogens
into depurinating mutagens. Lpo is transcriptionally activated by the
transcription factor KLF5, a target of miR-10a that is also depleted
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in miR10a–/–/Apcmin intestine. However, LPO levels are only
elevated in the colon of miR10a–/–/Apcmin mice, yet tumor
multiplicity is most evident in the small intestine, suggesting that
other pathways contribute to tumorigenesis downstream of miR-10a
(Stadthagen et al., 2013).
In vitro studies of CRC cell lines indicate that miR-100 and
miR-125b promote apoptosis, and thus may repress tumorigenesis,
or may be important for the sensitization of tumors to
chemotherapeutic drugs (Gong et al., 2013; Peng et al., 2014).
In contrast, miR-10b is upregulated in CRC, is associated with
metastasis and can repress the pro-apoptotic protein BIM (Nishida
et al., 2012). In CRC, miR-10b upregulation might promote
migration and invasion through the direct repression of HOXD10
(Wang et al., 2016). The repression of HOXD10 in turn stimulates
the increased expression of RHOC, a pro-metastatic small GTPase
that has been implicated in metastatic breast cancer (Ma et al.,
2007). However, despite expectations that miR-10b would be
elevated, levels of miR-10b are only subtly increased in CRC
tumors compared with normal intestinal tissue (Wang et al., 2016),
consistent with miRNA-sequencing studies by The Cancer
Genome Atlas (TCGA) project by the National Cancer Institute
(Jacobsen et al., 2013). Moreover, miR-10b levels are not globally
increased in metastatic breast cancer (Gee et al., 2008). If elevated
miR-10b levels drive tumorigenesis, this might occur only in a
distinct subpopulation of tumor cells, as hypothesized for breast
cancer (Gee et al., 2008) and as observed in circulating CRC cells
(Gasch et al., 2015), or miR-10b might play a temporally limited
role at a particular stage of tumorigenesis. Indeed, one study has
reported that miR-10b is depleted in CRC-associated liver
metastases, while its upregulation in primary CRC tumors is
predictive of distant metastasis (Hur et al., 2015). This suggests
that miR-10b might play a stage-specific role in the metastasis of
tumor cells, perhaps via EMT, while also having a counter-
productive effect in the establishment of metastases. This situation
is reminiscent of the effects that miR-200 has on breast cancer
metastasis, whereby miR-200 promotes MET to facilitate
metastasis (Korpal et al., 2011).
The miR-10 family certainly deserves further examination to
determine how individual members affect CRC tumorigenesis,
especially in light of the possibly pleiotropic effects or stage-
specific functions described above. Moreover, a role for miR-10
miRNAs in regulating metastasis seems evident, but needs further
scrutiny. One odd but significant feature of the arrangement of the
miR-10 gene family is that the miR-99, miR-100, and miR-125
genes (all except miR-10a/b) are physically clustered with the loci
that encode Let-7 miRNAs. One can certainly speculate that
chromosomal deletions or the transcriptional silencing of these
miR-10 genes might also affect Let-7 miRNAs as well, although
this has not yet been documented.
Let-7 and CRC tumorigenesis
Let-7 miRNAs account for 4 out of the 15 most abundant miRNAs
in mouse intestine (McKenna et al., 2010). Many functional studies
of Let-7 in CRC have uncovered important roles for these miRNAs
through overexpression of the specific and potent Let-7 inhibitors
LIN28A and LIN28B. In CRC cell lines, LIN28B overexpression
enhances migration and invasion, and these responses depend on
the depletion of Let-7 miRNAs by LIN28B (King et al., 2011b).
Studies in LIN28 transgenic mice have revealed that Let-7 miRNAs
are critical for repressing tumorigenesis in the intestine (Madison
et al., 2013, 2015; Tu et al., 2015). In vivo genetic studies of Let-7
function are lacking, probably because of high expression levels in
the intestine (McKenna et al., 2010) and redundancy (Abbott et al.,
2005) of this large miRNA gene family. Despite these hurdles, we
recently depleted all Let-7 miRNAs in the mouse intestine
epithelium by tissue-specific expression of LIN28B in
conjunction with an intestine-specific knockout of the Mirlet7c2/
Mirlet7b cluster (Madison et al., 2013, 2015). These genetic
manipulations caused the spontaneous development of
adenocarcinomas with a high penetrance, a phenotype that
depends on the Let-7 target Hmga2, a DNA-binding non-histone
high mobility group chromatin protein and likely oncogene
(Madison et al., 2015). Aside from Hmga2 (Boyerinas et al.,
2008; Gurtan et al., 2013), Let-7 miRNAs also repress IGF2BP1,
IGF2BP2, TRIM71 (which encode RNA-binding proteins) and
NR6A1 (an orphan nuclear receptor) (Boyerinas et al., 2008; Gurtan
et al., 2013). Among these, IGF2BP1 is a transcriptional target of
Wnt-TCF4/β-catenin signaling and promotes tumorigenesis and
metastasis in CRC cell lines and mouse models (Noubissi et al.,
2006; Hamilton et al., 2013).
Let-7 miRNAs are among the most important miRNAs for
repressing tumorigenesis because of their abundance, anti-
proliferative function and pro-differentiation effects. Therefore,
augmenting Let-7 miRNA function may be key for the prevention or
treatment of CRC. Despite the abundance and redundancy of the 12-
member Let-7 miRNA gene family, they are largely susceptible to
the overexpression of either LIN28A or LIN28B in CRC, which can
function as potent oncogenes (Viswanathan et al., 2009). In other
cancers LIN28B can be induced by oncogenic drivers that are
activated in CRC – by NFΚB (Iliopoulos et al., 2009) and Wnt
signaling (Cai et al., 2013) in breast cancer and by MYC in a B-cell
lymphoma cell line (Chang et al., 2009) – although direct relevance
to CRC remains to be determined.
miR-15 anti-oncomiR family
The miR-15 family (miR-15, miR-16, miR-195) can also include
miR-424 and miR-497. MiR-16 and miR-195 are depleted in
CRC tumors relative to normal tissue (Wang et al., 2012; Qian
et al., 2013; Xiao et al., 2014). Mechanistically, the miR-15a/
miR-16-1 locus is induced by TP53 in response to DNA damage
and is responsible for directly repressing the pro-metastatic
bHLH transcription factor AP-4 (TFAP4) in CRC cells (Shi
et al., 2014). Shi et al. (2014) demonstrated using mouse
xenograft models of lung metastasis that the repressive effects of
miR-15a/16 on migration, invasion, and EMT are due to their
direct repression of TFAP4. As is frequently observed for
miRNAs, the authors also uncovered a negative feedback loop,
whereby TFAP4 directly represses the transcription of the miR-
15a/miR-16-1 locus.
Pleiotropic effects of miR-200 miRNAs
Multiple miRNAs appear to have pleiotropic or context-dependent
effects in CRC. Such effects are not wholly understood, except in
the case of the miR-200 family. This family is often reported as an
important factor in maintaining epithelial identity and in repressing
EMT (Zaravinos, 2015); however, miR-200 miRNAs can also
promote metastasis, through effects on MET – a process that can
promote the establishment of a metastasis (Korpal et al., 2011;
Diepenbruck and Christofori, 2016). The miR-200 family consists
of miR-200a/b/c, miR-141 and miR-429, which are located in two
gene clusters in mice and humans. These miRNAs repress the pro-
mesenchymal transcription factors ZEB1, ZEB2 and PRRX1 (Park
et al., 2008). Consistent with their role in repressing growth and
EMT in primary tumors, miR-200 miRNAs are downregulated in
205


















CRC tumors via promoter methylation, and they function in a cell-
autonomous manner in tumor epithelium (Davalos et al., 2012).
Definitive studies demonstrating a pleiotropic role for miR-200 in
CRC are lacking; however, descriptive studies suggest that miR-200
miRNAs might promote the establishment of metastases.
Specifically, miR-200c and miR-141 have been shown to be
elevated in liver metastases relative to levels in primary CRC tumors
(Hur et al., 2013). Serum levels of miR-200c are also elevated in
individuals with CRC metastases, although the source of these
miRNAs might originate from non-tumor cells (Toiyama et al.,
2014). The observed differential methylation of miR-200 promoters
between primary tumors and metastases might also reflect the need
for plasticity of miR-200 expression (Davalos et al., 2012),
depending on the context and tumor environment (Hur et al.,
2013). MiR-200 is also regulated by the transcription factor ASCL2,
which transactivates the miR-200b-a-429 promoter (Tian et al.,
2014). ASCL2 is aWnt target gene that promotes stem cell fate in the
intestine (van der Flier et al., 2009; Schuijers et al., 2015) and is
upregulated in CRC (Jubb et al., 2006). Dynamic levels of ASCL2,
whose promoter can be methylated and repressed (de Sousa et al.,
2011), might also contribute to the context-dependent expression of
miR-200.
Despite the evidence that miR-200 miRNAs could promote the
establishment of metastasis, such a role remains to be fully
examined in CRC. Further studies may require the controlled
transgenic expression (or inactivation) of miR-200 miRNAs in
animal models to dissect stage-specific or context-specific roles for
miR-200.
miRNAs as diagnostic and prognostic tools
Screening and early detection of cancer is the main approach for
CRC prevention in the USA and Europe, in which both fecal occult
blood tests (FOBT, see Glossary, Box 1) and colonoscopy are used
together or alone, for those with an average risk for CRC at age 50
(Zavoral et al., 2009; Altobelli et al., 2014; Sovich et al., 2015). For
individuals with an increased risk, such as those with affected
family members, IBD, familial adenomatous polyposis (FAP) or
Lynch syndrome, screening by colonoscopy is usually
recommended earlier and more frequently. FOBT is a yearly, non-
invasive screening technique that detects blood in stool and provides
an estimated 24-39% reduction in mortality due to CRC; however,
this method suffers from low sensitivity. Often, a positive FOBT
results in colonoscopy screening, which is normally recommended
every 10 years (Sovich et al., 2015). Colonoscopy is the most
prevalent screening method for CRC used in the USA and allows
evaluation of both the right and left colon, in addition to the removal
of large polyps during the procedure. Although this method reduces
the odds of CRC by 30-75%, it is estimated that nearly 25% of
polyps are missed during colonoscopy, and it is a costly and
invasive technique (van Rijn et al., 2006; Leufkens et al., 2012;
Sovich et al., 2015). Given these caveats, cheaper, less-invasive and
more quantitative tests would provide an attractive alternative to the
current standard screening methods. MiRNAs in blood or stool may
provide this alternative.
On a practical level, miRNAs can be used to screen patients for
cancer because they are stable and detectable in blood and stool, and
their expression profiles reflect their expression in tumors fromCRC
patients (Dong et al., 2011; Ren et al., 2015). Ideally, screening
tests should detect the presence of miRNAs found exclusively in
individuals with intestinal adenomas or CRC. Although the use
of miRNAs to screen for CRC might never out-perform the
preventative successes of routine colonoscopy, their use could offer
less-invasive and more cost-effective alternatives to supplement
existing screening approaches.
The use of miRNAs for prognostic purposes also holds promise,
especially with the implementation of precision medicine in CRC
therapy (an approach that takes into account individual variations in
gene expression and tumor phenotypes to achieve optimal patient
outcomes through tailored therapies). New improvements to
miRNA detection technologies such as digital PCR (see Glossary,
Box 1) could enable more sensitive methods for the absolute
quantification of miRNAs, as recently demonstrated for lung cancer
(Li et al., 2014a; Wang et al., 2015a; Campomenosi et al., 2016).
The expression signatures of multiple miRNAs and mRNAs could
also provide effective diagnostic and prognostic assays for CRC (Li
et al., 2014a; Conte et al., 2015).
MiR-21 is perhaps the most studied oncomiR implicated in CRC,
as previously discussed. Mir-21 is elevated in CRC tumors, with
several studies reporting a step-wise increase in its expression as
tumors progress to later stages (see Fig. 1) (Kjaer-Frifeldt et al.,
2012; Schee et al., 2012; Toiyama et al., 2013). MiR-21 is also
increased in the serum and stool of CRC patients and can accurately
predict the local tumor invasion depth (T), lymph node involvement
(N) and the presence of distant metastases (M) – collectively, the
TNM stage (Kulda et al., 2010; Link et al., 2010; Toiyama et al.,
2013; Hofsli et al., 2013; Ogata-Kawata et al., 2014; Bastaminejad
et al., 2016). In addition, high levels of miR-21 in primary CRC
tissues and matched serum samples are associated with large tumor
size and with distant metastasis (Toiyama et al., 2014). HighmiR-21
expression in tumors is also associated with poor response to
chemotherapy and decreased disease-free survival (Schetter et al.,
2008; Kulda et al., 2010; Shibuya et al., 2010; Oue et al., 2014).
Levels of circulating miR-21 nevertheless decrease following CRC
tumor resection (Toiyama et al., 2013). These studies demonstrate
that miR-21 in serum and stool reflect its levels in CRC tumors; it
thus might serve as both a diagnostic and prognostic biomarker by
predicting TNM stage, potential metastasis and responsiveness to
chemotherapy. However, increased miR-21 serum levels have also
been reported for pancreatic, lung and breast cancers (Volinia et al.,
2006; Yan et al., 2008; Toiyama et al., 2013), suggesting that stool
analysis should be incorporated to enhance the specificity of CRC
screening.
The miR-17-92 cluster is involved in driving tumorigenesis, as
discussed above. Several members of this cluster, such as miR-17
(Ng et al., 2009; Yu et al., 2012), miR-20a (Schetter et al., 2008;
Motoyama et al., 2009; Earle et al., 2010; Yu et al., 2012), miR-92a
(Motoyama et al., 2009; Ng et al., 2009; Earle et al., 2010; Tsuchida
et al., 2011; Schee et al., 2012; Wu et al., 2012; Yu et al., 2012) and
miR-18a (Motoyama et al., 2009; Brunet Vega et al., 2013; Zhang
et al., 2013b), are all reportedly increased in CRC tumors and in
serum/plasma, with their elevated levels correlating with recurrence
and poor prognosis. Importantly, serum levels of miR-18a (Zhang
et al., 2013b) and miR-92a (Huang et al., 2010; Wu et al., 2012)
miRNAs decrease following tumor resection. Tests of isolated
colonic epithelial cells from the stool of CRC patients have also
demonstrated the increased expression of the miR-17-92 cluster
(Koga et al., 2010). Overexpression of miR-17-92 has also been
reported in other malignancies, including hepatocellular carcinoma,
leukemia, pancreatic, breast, ovarian and lung cancer (Ohyashiki
et al., 2010; Shigoka et al., 2010; Volinia et al., 2006; Mogilyansky
and Rigoutsos, 2013). Such a broad expression profile might limit
the effectiveness of this miRNA as a specific biomarker for CRC;
however, screening for miR-17-92 in the serum and stool of CRC
patients could prove to be a useful prognostic indicator.
206


















The oncomiR miR-29a is also upregulated in tumors (Slattery
et al., 2011) and in the blood of CRC patients, which can be used to
accurately distinguish patients with early CRC and advanced
adenomas (Brunet Vega et al., 2013; Dong et al., 2011; Huang et al.,
2010; Luo et al., 2013; Wang and Gu, 2012). In CRC fecal samples,
miR-29a was specifically elevated in individuals with rectal tumors,
but not colonic tumors (Zhu et al., 2016). MiR-29a has also been
proposed as a marker for the early detection of colorectal liver
metastasis (CRLM), as levels were significantly higher in both
tumors and serum of CRLM patients (Wang and Gu, 2012). This
miRNA is also elevated in the serum of patients with multiple
myeloma (Sevcikova et al., 2013), but has most extensively been
studied as a potential diagnostic biomarker for CRC. The use of
miR-29a as a prognostic biomarker for CRC is less clear, but an
increase in its levels could indicate early metastasis (Wang and Gu,
2012).
MiR-200c is an oncomiR that promotes epithelial fate, but it can
also enhance metastasis (Toiyama et al., 2014). The silencing of
miR-200c results in apoptosis and decreased invasion in CRC cell
lines (Hur et al., 2013; Chen et al., 2014b; Tanaka et al., 2015). This
miRNA is upregulated in CRC tumors and is associated with
decreased patient survival, but it is not associated with TNM stage
(Xi et al., 2006; Zhang et al., 2013b; Chen et al., 2014b). MiR-200c
levels are also elevated in the plasma of CRC patients and decrease
after the surgical resection of tumors (Zhang et al., 2013b). In
another study, serum levels of miR-200c were specifically increased
for stage IV CRC compared with other stages and normal controls,
and were also increased in lymph node, liver and other distant
metastases (Toiyama et al., 2014). Levels of miR-200c in liver
metastases correlate with levels in primary CRC tumors, and miR-
200c levels are significantly increased in both the metastasis and the
primary tumor, relative to normal adjacent colonic tissue (Hur et al.,
2013; Toiyama et al., 2014). Together, these studies demonstrate the
potential of miR-200c as a marker for distant metastasis in CRC.
Increased miR-200c serum levels in CRC patients also reportedly
indicate decreased patient survival (Toiyama et al., 2014).
Many studies demonstrate that the evaluation of miRNAs as
biomarkers for CRC in blood and stool is promising, although
several challenges remain to be addressed. Notably, several of the
miRNAs discussed are altered in cancers other than CRC, and this
hinders their use as specific biomarkers of CRC (although the ability
to detect multiple cancers could also be seen as an advantage). The
implementation of techniques such as digital PCR in diagnostic
assays might yield greater sensitivity. Digital PCR is able to detect
smaller fold changes in miRNA expression than quantitative PCR
(qPCR) and is therefore a highly sensitive and precise technique that
can be used with clinical samples (Li et al., 2014a; Wang et al.,
2015a).
The altered expression of miRNAs has been reported in CRC
tumors and might in the future be used as diagnostic tools and
prognostic indicators for CRC. The measurement of miRNAs in the
blood or stool could complement current screening methods for
CRC and might also provide new insights into mechanisms of
tumorigenesis and metastasis. In addition, FOBT samples already
collected for CRC screening could be utilized for miRNA analysis
(Link et al., 2010). Moreover, miRNAs in stool would serve as an
ideal test for the early diagnosis of CRC if altered miRNA levels can
be detected earlier in this material than in the blood (Muhammad
et al., 2014). An assay that examines the expression of both
oncogene and tumor suppressor miRNAs might provide the most
comprehensive assessment for diagnostic and prognostic purposes.
Although the miRNAs discussed in this section are oncogenic, both
miR-215 (Chiang et al., 2012; Karaayvaz et al., 2011; Faltejskova
et al., 2012; Slattery et al., 2015) and miR-375 (Dai et al., 2012;
Faltejskova et al., 2012; Wang et al., 2014d; Xu et al., 2014, 2016)
are tumor-suppressive miRNAs that could be used for CRC
screening, although an analysis of miRNA levels in blood or stool
is needed.
Conclusions and future directions
As highlighted in this Review, miRNAs are undoubtedly drivers
and modulators of CRC tumorigenesis that have considerable
potential as biomarkers and therapeutic targets. Consistently,
miRNAs are observed to function in positive- or negative-
feedback loops (a biological phenomenon that probably extends
miRNA function beyond ‘fine tuning’), highlighting their relevance
in self-sustaining epigenetic switches that can change or reinforce
cellular phenotypes. Despite the numerous studies of miRNAs and
extensive analyses of their expression, the role and function of many
individual miRNAs in CRC remains poorly understood. The
integrated analysis of multiple miRNA targets for a given miRNA is
also needed; i.e. the de-regulation of multiple targets by an aberrant
miRNA raises the possibility of interaction, cooperation and
possibly synergy between co-regulated targets. The role of
miRNAs in tumor stroma also deserves more study, especially
considering that some miRNAs, such as miR-143 and miR-145, are
exclusively expressed in the stroma, with little likelihood of a cell-
autonomous role in CRC cells (Chivukula et al., 2014). High levels
of miR-21 are also reported in CRC stroma (Vicinus et al., 2013).
Together, the use of miRNAs as biomarkers for CRC might provide
a new, less-invasive technique to screen for CRC and to help
determine prognosis. We propose that a screening panel consisting
of multiple miRNAs might provide the most precise and effective
screening tool for CRC.
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